Tacrolimus Level Monitoring Test
Order a whole blood trough concentration (C0) measurement using either LC-MS/MS or immunoassay methodology, with the specimen collected in EDTA-anticoagulated tubes immediately before the next scheduled dose. 1
Specimen Collection Requirements
- Collect whole blood in EDTA-anticoagulated tubes – this is the required matrix for tacrolimus measurement 1
- Avoid heparin anticoagulation due to the tendency to form clots during storage 1
- Timing is critical: Draw the trough level immediately before the next dose to accurately assess C0 concentrations 1
Laboratory Methodology Options
Two primary assay methods are available, each with distinct characteristics:
LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry)
- Measures only parent tacrolimus compound without metabolite cross-reactivity 1
- Provides more accurate representation of the active drug 2
- Important caveat: LC-MS/MS typically yields lower values than immunoassay (approximately 10-40% lower depending on formulation) because it excludes metabolites 2, 3
Immunoassay Methods
- May cross-react with tacrolimus metabolites, potentially yielding higher values than LC-MS/MS 1
- The positive bias relative to LC-MS/MS varies by specific assay and laboratory 1
- Less reliable at concentrations below 9 ng/mL, with higher inter-laboratory variability in this range 4
Critical Monitoring Considerations
- Assay method matters for interpretation: If your institution switches from immunoassay to LC-MS/MS, therapeutic targets may need adjustment to prevent toxicity 3
- One study demonstrated increased acute kidney injury risk when LC-MS/MS monitoring used target ranges originally derived from immunoassay values 3
- Formulation affects measurement bias: The difference between immunoassay and LC-MS/MS is significantly smaller for extended-release tacrolimus (Envarsus) compared to immediate-release formulations 2
When to Check Levels
- During the first week post-transplant when concentrations are most variable 1
- With any medication change that could affect tacrolimus concentrations (especially non-dihydropyridine calcium channel blockers like diltiazem or verapamil) 5
- With changes in patient status affecting drug metabolism (hepatic or renal dysfunction) 1
- Every 2-3 months in stable transplant recipients as part of routine monitoring 5